0001437749-25-033354 | 10-Q | XBRL Viewer

Note 9 - Related Party Transactions	9 Months Ended
Sep. 30, 2025
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	9. Related Party Transactions On July 3, 2024, the Company announced the closing of its 2024 Rights Offering. The 2024 Rights Offering resulted in the sale of six million 2024 Units, at a price of $10.00 per 2024 Unit. Each 2024 Unit consisted of one share of the Company’s common stock, par value $0.001 per share, and two warrants, each being a warrant to purchase one-half of one share of common stock. The common stock and warrants comprising the 2024 Units separated upon the closing of the 2024 Rights Offering and were issued individually. A total of 5,999,998 shares of common stock and warrants to acquire up to approximately an additional six million shares of common stock were issued in the offering. The Company received aggregate gross proceeds from the 2024 Rights Offering of $60 million. Robert W. Duggan, the Company’s majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the 2024 Rights Offering. See Note 6 for further details.

Note 9 - Related Party Transactions

9 Months Ended

Sep. 30, 2025

9. Related Party Transactions

On July 3, 2024, the Company announced the closing of its 2024 Rights Offering. The 2024 Rights Offering resulted in the sale of six million 2024 Units, at a price of $10.00 per 2024 Unit. Each 2024 Unit consisted of one share of the Company’s common stock, par value $0.001 per share, and two warrants, each being a warrant to purchase one-half of one share of common stock. The common stock and warrants comprising the 2024 Units separated upon the closing of the 2024 Rights Offering and were issued individually. A total of 5,999,998 shares of common stock and warrants to acquire up to approximately an additional six million shares of common stock were issued in the offering. The Company received aggregate gross proceeds from the 2024 Rights Offering of $60 million. Robert W. Duggan, the Company’s majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the 2024 Rights Offering. See Note 6 for further details.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 95,214	$ 118,038
Accounts receivable	15	0
Inventory	57	0
Prepaid expenses and other current assets	1,871	1,411
Total current assets	97,157	119,449
Property and equipment, net	1,055	1,160
Intangible assets, net	741	1,220
Goodwill	2,791	2,791
Right-of-use assets	6,316	7,163
Other assets	705	677
Total assets	108,765	132,460
Current liabilities:
Accounts payable	2,978	1,673
Accrued expenses	5,203	7,027
Lease liability, current	1,519	1,355
Total current liabilities	9,700	10,055
Lease liability, less current portion	6,371	7,543
Total liabilities	16,071	17,598
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value; authorized – 50,000 shares; no shares issued and outstanding	0	0
Common stock, $0.001 par value; authorized – 500,000 shares; issued and outstanding – 67,738 shares and 65,926 shares as of September 30, 2025 and December 31, 2024, respectively	68	66
Additional paid-in capital	538,474	505,296
Accumulated deficit	(445,848)	(390,500)
Total stockholders’ equity	92,694	114,862
Total liabilities and stockholders’ equity	$ 108,765	$ 132,460

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands	Sep. 30, 2025	Dec. 31, 2024
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	50,000	50,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	500,000	500,000
Common stock, shares issued (in shares)	67,738	65,926
Common stock, shares outstanding (in shares)	67,738	65,926

Note 3 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Total assets measured at fair value	$ 90,156	$ 113,776
Fair Value, Inputs, Level 1 [Member]
Total assets measured at fair value	90,156	113,776
Fair Value, Inputs, Level 2 [Member]
Total assets measured at fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Total assets measured at fair value	0	0
Money Market Funds [Member]
Cash and Cash equivalents	90,156	113,776
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash and Cash equivalents	90,156	113,776
Money Market Funds [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash and Cash equivalents	0	0
Money Market Funds [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash and Cash equivalents	$ 0	$ 0

Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Stock Option Activity (Details) - The 2015 Plan, 2017 Plan and Inducement Plan [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2025 $ / shares shares	Dec. 31, 2024 $ / shares shares
Options balances, number of shares (in shares) \| shares	10,979,332
Options balances, weighted average exercise price (in dollars per share) \| $ / shares	$ 9.59
Options balances, weighted average remaining life (Year)	7 years 2 months 26 days	7 years 1 month 9 days
Options granted, number of shares (in shares) \| shares	2,884,343
Options granted, weighted average exercise price (in dollars per share) \| $ / shares	$ 18.67
Options exercised, number of shares (in shares) \| shares	(493,431)
Options exercised, weighted average exercise price (in dollars per share) \| $ / shares	$ 4.26
Options canceled, number of shares (in shares) \| shares	(66,500)
Options canceled, weighted average exercise price (in dollars per share) \| $ / shares	$ 13.13
Options expired, number of shares (in shares) \| shares	0
Options expired, weighted average exercise price (in dollars per share) \| $ / shares	$ 0
Options balances, number of shares (in shares) \| shares	13,303,744	10,979,332
Options balances, weighted average exercise price (in dollars per share) \| $ / shares	$ 11.74	$ 9.59
Options exercisable, number of shares (in shares) \| shares	4,806,075
Options exercisable, weighted average exercise price (in dollars per share) \| $ / shares	$ 13.44
Options exercisable, weighted average remaining life (Year)	5 years 2 months 12 days

Note 8 - Segment Reporting - Reconciliation of Net Loss (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2025

Sep. 30, 2024

Sep. 30, 2025

Sep. 30, 2024

Product revenue

$ 86

$ 0

$ 86

$ 0

Adjusted cost of product revenue

279

Total other income, net

982

975

3,338

1,796

Net loss

(19,385)

(12,680)

(55,348)

(34,200)

Operating Segments [Member]

Product revenue

Adjusted cost of product revenue

^[1]

172

Cross platform research and engineering

^[2]

3,546

3,084

11,133

9,586

R&D manufacturing and engineering

^[3]

2,328

1,376

6,658

3,498

Clinical and regulatory

^[4]

2,363

1,245

5,902

2,913

General and administrative

^[5]

3,993

3,861

11,611

10,378

Sales and marketing

^[6]

2,177

813

5,997

1,937

Other segment items

^[7]

5,874

3,276

17,299

7,684

Total other income, net

(982)

(975)

(3,338)

(1,796)

Net loss

$ (19,385)

$ (12,680)

$ (55,348)

$ (34,200)

[1]	Adjusted cost of product revenue includes material costs, cash compensation costs, fees paid to consultants and outside service providers and organizations, and other expenses relating to manufacturing the Company’s commercial products. It does not include stock-based compensation, depreciation, or amortization - see Other Segment Items described in footnote 7 below.
[2]	Cross platform research and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, prototype spending and other expenses relating to the acquisition, design and development of the Company’s clinical stage devices.
[3]	R&D manufacturing and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with the procurement of materials and the manufacturing of the Company’s clinical stage devices.
[4]	Clinical and regulatory includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with clinical trials and regulatory approvals required for the development of the Company’s clinical stage devices.
[5]	General and administrative includes compensation costs and fees paid to consultants and outside service providers and organizations in support of the administrative functions of the Company, including finance, legal, human resources, IT and facilities.
[6]	Sales and marketing includes compensation costs, fees paid to consultants and outside service providers and organizations, costs associated with marketing and sales strategy as well as execution of marketing and sales initiatives for the Company's products.
[7]	Other segment items includes stock-based compensation, depreciation and amortization.

Note 3 - Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Fair Value Disclosures [Text Block]

3. Fair Value of Financial Instruments

The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below.

Level 1 - Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include money market funds.

Level 2 - Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. The Company did not classify any of its investments within Level 2 of the fair value hierarchy.

Level 3 - Unobservable inputs for which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. The Company did not classify any of its investments within Level 3 of the fair value hierarchy.

The following table sets forth the fair value of the Company’s financial instruments measured on a recurring basis as of September 30, 2025 and December 31, 2024, respectively (in thousands):

		September 30, 2025
Assets	Classification	Level 1		Level 2		Level 3		Total
Money market funds	Cash and cash equivalents	$	90,156	$	—	$	—	$	90,156
Total assets measured at fair value		$	90,156	$	—	$	—	$	90,156

		*December 31, 2024*
Assets	*Classification*	*Level 1*		*Level 2*		*Level 3*		*Total*
Money market funds	Cash and cash equivalents	$	113,776	$	—	$	—	$	113,776
Total assets measured at fair value		$	113,776	$	—	$	—	$	113,776

The Company did not have any financial liabilities measured on a recurring basis as of September 30, 2025 or December 31, 2024.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Note 4 - Balance Sheet Components - Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Compensation expense	$ 3,588	$ 4,097
Clinical trial fees and costs	953	284
Professional fees	311	564
Legal settlement	0	1,196
Severance	0	698
Other	351	188
Total accrued expenses	$ 5,203	$ 7,027

Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Nine Months Ended September 30,
	*2025*		*2024*
Common stock warrants		205,953		5,857,680
Common stock options		13,303,744		12,327,332
Total		13,509,697		18,185,012

Insider Trading Arrangements	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2025 shares
Trading Arrangements, by Individual [Table]
Material Terms of Trading Arrangement [Text Block]	Item 5. Other Information Trading Arrangements Except as noted below, during the nine-months ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Item 408 of Regulation S-K. On May 14, 2025, Kevin Danahy, the Company’s Chief Commercial Officer, adopted a Rule 10b5‑1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act for the exercise of vested options and the sale of up to 150,000 shares of common stock between August 13, 2025 and May 1, 2026 (the “Sales Period”), net of shares to satisfy withholding obligations, so long as the market price of the Company’s common stock during the Sales Period is higher than certain minimum thresholds specified in his trading plan. On June 12, 2025, Darrin Uecker, the Company’s Chief Technology Officer and a Director, adopted a Rule 10b5‑1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act for the exercise of expiring options and the sale of up to 120,000 shares of common stock between September 11, 2025 and September 20, 2025, net of shares to satisfy withholding obligations, so long as the market price of the Company’s common stock during the Sales Period was higher than a certain minimum threshold specified in his trading plan.
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Kevin Danahy [Member]
Trading Arrangements, by Individual [Table]
Trading Arrangement, Securities Aggregate Available Amount	150,000
Trading Arrangement Adoption Date	May 14, 2025
Trading Arrangement, Individual Name	Kevin Danahy
Trading Arrangement, Individual Title	Chief Commercial Officer
Rule 10b5-1 Arrangement Adopted [Flag]	true
Darrin Uecker [Member]
Trading Arrangements, by Individual [Table]
Trading Arrangement, Securities Aggregate Available Amount	120,000
Trading Arrangement Adoption Date	June 12, 2025
Trading Arrangement, Individual Name	Darrin Uecker
Trading Arrangement, Individual Title	Chief Technology Officer and a Director
Rule 10b5-1 Arrangement Adopted [Flag]	true

Note 6 - Stockholders' Equity and Stock-based Compensation - ESPP Assumptions (Details) - The 2017 Employee Stock Purchase Plan [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Expected volatility	98.00%	98.00%	98.00%	98.00%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Expected term in years (Year)	6 months	6 months	6 months	6 months
Risk-free interest rate	3.80%	4.40%	3.80%	4.90%
Maximum [Member]
Expected term in years (Year)	1 year	1 year	1 year	1 year
Risk-free interest rate	4.00%	5.30%	4.30%	5.30%

Note 9 - Related Party Transactions (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Jul. 03, 2024	Sep. 30, 2025	Dec. 31, 2024	Mar. 28, 2024
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001	$ 0.001
Warrants Issued in 2024 Rights Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	0.5			0.5
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	5,999,999	205,953
Warrants Issued in 2024 Rights Offering [Member] \| Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,000,000
The 2024 Right Offering [Member]
Equity Offering, Units, Maximum Amount Authorized (in shares)	6,000,000			6,000,000
Shares Issued, Price Per Share (in dollars per share)	$ 10			$ 10
Number of Shares Per Unit Issued (in shares)	1			1
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001			$ 0.001
Number of Warrants in Each Unit (in shares)	2			2
Stock Issued During Period, Shares, New Issues (in shares)	5,999,998
Proceeds from Issuance or Sale of Equity	$ 60
The 2024 Right Offering [Member] \| Majority Stockholder and Co-chairman [Member]
Percent of Offering Purchased	88.00%

Note 6 - Stockholders' Equity and Stock-based Compensation - Option Assumptions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Time-based and Performance Options [Member]
Risk-free interest rate		4.50%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Time-based and Performance Options [Member] \| Minimum [Member]
Expected term in years (Year)	5 years 2 months 12 days	5 years	5 years	5 years
Expected volatility	93.00%	93.00%	93.00%	91.00%
Risk-free interest rate	4.00%		4.00%	4.00%
Time-based and Performance Options [Member] \| Maximum [Member]
Expected term in years (Year)	6 years 3 months 18 days	6 years 3 months 18 days	6 years 10 months 24 days	6 years 3 months 18 days
Expected volatility	95.00%	97.00%	100.00%	97.00%
Risk-free interest rate	4.10%		4.60%	4.50%
Market-based Options [Member]
Expected volatility	90.00%	90.00%	90.00%	90.00%
Risk-free interest rate	3.90%	3.90%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Market-based Options [Member] \| Minimum [Member]
Expected term in years (Year)	2 years 2 months 12 days	2 years 2 months 12 days	2 years 2 months 12 days	2 years 2 months 12 days
Risk-free interest rate			3.90%	3.90%
Market-based Options [Member] \| Maximum [Member]
Expected term in years (Year)	4 years 6 months	4 years 2 months 12 days	7 years	5 years 9 months 18 days
Risk-free interest rate			4.60%	4.40%
Performance-based and Market-based Options [Member]
Expected volatility	0.00%	0.00%	90.00%	0.00%
Risk-free interest rate	0.00%	0.00%		0.00%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Performance-based and Market-based Options [Member] \| Minimum [Member]
Expected term in years (Year)			6 years 1 month 6 days
Risk-free interest rate			4.40%
Performance-based and Market-based Options [Member] \| Maximum [Member]
Expected term in years (Year)			8 years 10 months 24 days
Risk-free interest rate			4.60%

Note 4 - Balance Sheet Components - Intangible Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Less: Accumulated amortization	$ (7,264)	$ (6,765)
Total	741	1,220
Acquired Patents and Licenses [Member]
Acquired patents and licenses	$ 8,005	$ 7,985

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Rights Offering Warrants [Member] Common Stock [Member]	Rights Offering Warrants [Member] Additional Paid-in Capital [Member]	Rights Offering Warrants [Member] Retained Earnings [Member]	Rights Offering Warrants [Member]	Rights Offering [Member] Common Stock [Member]	Rights Offering [Member] Additional Paid-in Capital [Member]	Rights Offering [Member] Retained Earnings [Member]	Rights Offering [Member]	ATM Offering [Member] Common Stock [Member]	ATM Offering [Member] Additional Paid-in Capital [Member]	ATM Offering [Member] Retained Earnings [Member]	ATM Offering [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2023													55,144
Balance at Dec. 31, 2023													$ 55	$ 381,220	$ (336,915)	$ 44,360
Issuance of common stock upon exercise of stock options (in shares)													111
Issuance of common stock upon exercise of stock options													$ 0	498	0	498
Issuance of common stock under employee stock purchase plan (in shares)													118
Issuance of common stock under employee stock purchase plan													$ 0	478	0	478
Issuance of common stock pursuant to warrant exercise (in shares)													142
Issuance of common stock pursuant to warrant exercise													$ 1	1,565	0	1,566
Stock-based compensation expense													0	6,793	0	6,793
Net loss													$ 0	0	(34,200)	(34,200)
Balance (in shares) at Sep. 30, 2024													61,516
Balance at Sep. 30, 2024													$ 62	450,184	(371,115)	79,131
Issuance of shares (in shares)					6,000				1
Issuance of shares					$ 6	$ 59,630	$ 0	$ 59,636	$ 0	$ 0	$ 0	$ 0
Issuance of equity-classified subscription rights as part of rights offering (Note 6)													0	47,700	0	47,700
Rights offering deemed pro-rata distribution to shareholders (Note 6)													$ 0	(47,700)	0	(47,700)
Balance (in shares) at Jun. 30, 2024													55,228
Balance at Jun. 30, 2024													$ 55	385,349	(358,435)	26,969
Issuance of common stock upon exercise of stock options (in shares)													105
Issuance of common stock upon exercise of stock options													$ 0	476	0	476
Issuance of common stock under employee stock purchase plan (in shares)													40
Issuance of common stock under employee stock purchase plan													$ 0	182	0	182
Issuance of common stock pursuant to warrant exercise (in shares)													142
Issuance of common stock pursuant to warrant exercise													$ 1	1,565	0	1,566
Stock-based compensation expense													0	2,982	0	2,982
Net loss													$ 0	0	(12,680)	(12,680)
Balance (in shares) at Sep. 30, 2024													61,516
Balance at Sep. 30, 2024													$ 62	450,184	(371,115)	79,131
Issuance of shares (in shares)					6,000				1
Issuance of shares					$ 6	$ 59,630	$ 0	$ 59,636	$ 0	$ 0	$ 0	$ 0
Balance (in shares) at Dec. 31, 2024													65,926
Balance at Dec. 31, 2024													$ 66	505,296	(390,500)	114,862
Issuance of common stock upon exercise of stock options (in shares)													493
Issuance of common stock upon exercise of stock options													$ 1	2,099	0	2,100
Issuance of common stock under employee stock purchase plan (in shares)													45
Issuance of common stock under employee stock purchase plan													$ 0	593	0	593
Issuance of common stock pursuant to warrant exercise (in shares)	1,274
Issuance of common stock pursuant to warrant exercise	$ 1	$ 13,999	$ 0	$ 14,000
Stock-based compensation expense													0	16,487	0	16,487
Net loss													$ 0	0	(55,348)	(55,348)
Balance (in shares) at Sep. 30, 2025													67,738
Balance at Sep. 30, 2025													$ 68	538,474	(445,848)	92,694
Rights offering deemed pro-rata distribution to shareholders (Note 6)																0
Balance (in shares) at Jun. 30, 2025													67,278
Balance at Jun. 30, 2025													$ 67	530,883	(426,463)	104,487
Issuance of common stock upon exercise of stock options (in shares)													439
Issuance of common stock upon exercise of stock options													$ 1	1,707	0	1,708
Issuance of common stock under employee stock purchase plan (in shares)													19
Issuance of common stock under employee stock purchase plan													$ 0	241	0	241
Issuance of common stock pursuant to warrant exercise (in shares)	2
Issuance of common stock pursuant to warrant exercise	$ 0	$ 25	$ 0	$ 25
Stock-based compensation expense													0	5,618	0	5,618
Net loss													$ 0	0	(19,385)	(19,385)
Balance (in shares) at Sep. 30, 2025													67,738
Balance at Sep. 30, 2025													$ 68	$ 538,474	$ (445,848)	$ 92,694

Note 1 - Description of the Business

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. Description of the Business

Pulse Biosciences, Inc. is a novel ablation company committed to health innovation using its patented Nano-pulse Stimulation (“NPS”) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation (“nsPFA”) energy when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. The Company developed its proprietary nPulse System (formerly known as CellFX), a novel nsPFA delivery platform, and commercialized the initial application of its nsPFA energy to treat benign lesions of the skin. In parallel, the Company has designed a variety of applicators, or disposables, to explore the potential use of the nPulse platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and otolaryngology. These applicators include devices for open surgical procedures, endoscopic or minimally invasive procedures, and endoluminal catheters, and each has been used in preclinical studies. Based on its preclinical experience and the potential to significantly improve outcomes for patients in a large and growing market, the Company decided in 2022 to focus its primary efforts on the use of nsPFA energy and the nPulse platform in the treatment of atrial fibrillation ("AF") and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

The Company is incorporated in the State of Delaware. It is located in Miami, Florida, and continues to maintain its offices in Hayward, California. The Company maintains a website at www.pulsebiosciences.com where general information about the Company is available.

The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company does not currently have any material cash flows from operations. It has recently commenced revenue-generating operations and will need to raise additional capital to finance its operations. However, there can be no assurances that the Company will be able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its operating requirements.

Note 4 - Balance Sheet Components (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Depreciation	$ 100	$ 100	$ 313	$ 391

Note 5 - Goodwill (Details Textual) $ in Thousands	9 Months Ended	12 Months Ended
Note 5 - Goodwill (Details Textual) $ in Thousands	Sep. 30, 2025 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2024 USD ($)
Goodwill, Ending Balance	$ 2,791		$ 2,791
Goodwill, Impairment Loss	$ 0
Business Combination, Series of Individually Immaterial Business Combinations [Member]
Number of Businesses Acquired		3
Business Combination, Consideration Transferred, Total		$ 5,500
Goodwill, Ending Balance		$ 2,800

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 740
-Name Accounting Standards Codification
-Section 55
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478064/805-740-55-13

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-39

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

+ Details

- Definition

Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References + Details

Note 4 - Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Property, Plant and Equipment [Table Text Block]

	*September 30,*			*December 31,*
	*2025*			*2024*
Leasehold improvements	$	2,519		$	2,519
Laboratory equipment		1,522			1,342
Furniture, fixtures and equipment		966			966
Software		283			272
Construction in progress		46			29
Total property and equipment		5,336			5,128
Less: Accumulated depreciation and amortization		(4,281	)		(3,968	)
Total property and equipment, net	$	1,055		$	1,160

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	September 30,			December 31,
	2025			2024
Acquired patents and licenses	$	8,005		$	7,985
Less: Accumulated amortization		(7,264	)		(6,765	)
Total intangible assets, net	$	741		$	1,220

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Years ending December 31:
2025 (remaining 3 months)	$	166
2026		575
Total	$	741

Schedule of Accrued Liabilities [Table Text Block]

	*September 30,*		*December 31,*
	*2025*		*2024*
Compensation expense	$	3,588	$	4,097
Clinical trial fees and costs		953		284
Professional fees		311		564
Legal settlement		—		1,196
Severance		—		698
Other		351		188
Total accrued expenses	$	5,203	$	7,027

Note 8 - Segment Reporting

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

8. Segment Reporting

The Company conducts business as one operating and reportable segment relating to the research and development of the Company’s NPS technology. The Company's chief executive officer, who is the chief operating decision maker ("CODM"), views the Company’s operations and manages its business in one operating segment. The CODM uses the Company’s consolidated net loss to monitor actual results as compared to the budget in assessing segment performance and allocation of resources. Managing and allocating resources on an entity-wide basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CODM uses financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM is regularly provided with more detailed expense information than what is included in our condensed consolidated statement of operations and comprehensive loss. All product sales are in the United States and there are no significant groupings of product revenue the CODM considers or reviews when making operating decisions and assessing performance.

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under U.S. GAAP to the Company’s total net loss in the statements of operations (in thousands).

	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Product revenue	$	86		$	—		$	86		$	—

Adjusted cost of product revenue¹		172			—			172			—
Cross platform research and engineering²		3,546			3,084			11,133			9,586
R&D manufacturing and engineering³		2,328			1,376			6,658			3,498
Clinical and regulatory⁴		2,363			1,245			5,902			2,913
General and administrative⁵		3,993			3,861			11,611			10,378
Sales and marketing⁶		2,177			813			5,997			1,937
Other segment items⁷		5,874			3,276			17,299			7,684
Total other income, net		(982	)		(975	)		(3,338	)		(1,796	)
Net loss	$	(19,385	)	$	(12,680	)	$	(55,348	)	$	(34,200	)

___________________

1 Adjusted cost of product revenue includes material costs, cash compensation costs, fees paid to consultants and outside service providers and organizations, and other expenses relating to manufacturing the Company’s commercial products. It does not include stock-based compensation, depreciation, amortization, IT and facilities costs - see descriptions of Other segment items in footnote 7 and General and administrative in footnote 5 below.

2 Cross platform research and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, prototype spending and other expenses relating to the acquisition, design and development of the Company’s clinical stage devices.

3 R&D manufacturing and engineering includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with the procurement of materials and the manufacturing of the Company’s clinical stage devices.

4 Clinical and regulatory includes compensation costs, fees paid to consultants and outside service providers and organizations, and costs associated with clinical trials and regulatory approvals required for the development of the Company’s clinical stage devices.

5 General and administrative includes compensation costs and fees paid to consultants and outside service providers and organizations in support of the administrative functions of the Company, including finance, legal, human resources, IT and facilities.

6 Sales and marketing includes compensation costs, fees paid to consultants and outside service providers and organizations, costs associated with marketing and sales strategy as well as execution of marketing and sales initiatives for the Company's products.

7 Other segment items includes stock-based compensation, depreciation and amortization.

As of September 30, 2025, all of the Company’s long-lived assets are located in the United States.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2025 USD ($)
Inventory Write-down	$ 0

Note 8 - Segment Reporting (Details Textual)	3 Months Ended
Note 8 - Segment Reporting (Details Textual)	Sep. 30, 2025
Number of Reportable Segments	1
Number of Operating Segments	1

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Antidilutive securities (in shares)	13,509,697	18,185,012
Warrant [Member]
Antidilutive securities (in shares)	205,953	5,857,680
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	13,303,744	12,327,332

Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Property and equipment, gross	$ 5,336	$ 5,128
Less: Accumulated depreciation and amortization	(4,281)	(3,968)
Total property and equipment, net	1,055	1,160
Leasehold Improvements [Member]
Property and equipment, gross	2,519	2,519
Laboratory Equipment [Member]
Property and equipment, gross	1,522	1,342
Furniture and Fixtures [Member]
Property and equipment, gross	966	966
Software and Software Development Costs [Member]
Property and equipment, gross	283	272
Construction in Progress [Member]
Property and equipment, gross	$ 46	$ 29

Note 6 - Stockholders' Equity and Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	*2025*		*2024*		*2025*		*2024*
Cost of product revenue	$	52	$	—	$	52	$	—
Research and development		2,232		1,108		7,329		3,058
Selling, general and administrative		3,333		1,874		9,106		3,735
Total stock-based compensation expense	$	5,617	$	2,982	$	16,487	$	6,793

	Three Months Ended September 30,				Nine Months Ended September 30,
	*2025*		*2024*		*2025*		*2024*
Time-based options	$	3,937	$	2,131	$	11,623	$	4,609
Performance-based options		—		5		—		27
Market-based options		1,577		788		4,581		1,978
ESPP		103		58		283		179
Total stock-based compensation expense	$	5,617	$	2,982	$	16,487	$	6,793

The 2015 Plan, 2017 Plan and Inducement Plan [Member]

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	*Stock Options Outstanding*
	*Number of shares*			*Weighted average exercise price*		*Weighted average remaining life (in years)*
Balances — December 31, 2024		10,979,332		$	9.59		7.11
Options granted		2,884,343			18.67
Options exercised		(493,431	)		4.26
Options canceled		(66,500	)		13.13
Options expired		—			—
Balances — September 30, 2025		13,303,744		$	11.74		7.24
Exercisable — September 30, 2025		4,806,075		$	13.44		5.20

The 2017 Employee Stock Purchase Plan [Member]

Notes Tables

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Expected term in years		0.5 - 1.0		0.5 - 1.0		0.5 - 1.0		0.5 - 1.0
Expected volatility		98%		98%		98%		98%
Risk-free interest rate		3.8% - 4.0%		4.4% - 5.3%		3.8% - 4.3%		4.9% - 5.3%
Dividend yield		—		—		—		—

Share-Based Payment Arrangement, Option [Member]

Notes Tables

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Expected term in years		5.2 - 6.3		5.0 - 6.3		5.0 - 6.9		5.0 - 6.3
Expected volatility		93% - 95%		93% - 97%		93% - 100%		91% - 97%
Risk-free interest rate		4.0% - 4.1%		4.5%		4.0% - 4.6%		4.0% - 4.5%
Dividend yield		—		—		—		—

	Three Months Ended September 30,				Nine Months Ended September 30,
	*2025*		*2024*		*2025*		*2024*
Expected term in years		2.2 - 4.5		2.2 - 4.2		2.2 - 7.0		2.2 - 5.8
Expected volatility		90%		90%		90%		90%
Risk-free interest rate		3.9%		3.9%		3.9% - 4.6%		3.9% - 4.4%
Dividend yield		—		—		—		—

	Three Months Ended September 30,				Nine Months Ended September 30,
	*2025*		*2024*		*2025*		*2024*
Expected term in years		—		—		6.1 - 8.9		—
Expected volatility		—		—		90%		—
Risk-free interest rate		—		—		4.4% - 4.6%		—
Dividend yield		—		—		—		—

Note 4 - Balance Sheet Components

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Supplemental Balance Sheet Disclosures [Text Block]

4. Balance Sheet Components

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	*September 30,*			*December 31,*
	*2025*			*2024*
Leasehold improvements	$	2,519		$	2,519
Laboratory equipment		1,522			1,342
Furniture, fixtures and equipment		966			966
Software		283			272
Construction in progress		46			29
Total property and equipment		5,336			5,128
Less: Accumulated depreciation and amortization		(4,281	)		(3,968	)
Total property and equipment, net	$	1,055		$	1,160

Depreciation expense was $0.1 million for each of the three-months ended September 30, 2025 and 2024, and $0.3 million and $0.4 million for the nine-months ended September 30, 2025 and 2024, respectively.

Intangible Assets, Net

Intangible assets primarily consist of acquired licenses to utilize certain patents, know-how and technology relating to the Company’s NPS technology for biomedical applications acquired from Old Dominion University Research Foundation (“ODURF”), Eastern Virginia Medical School, and the University of Southern California. In addition, the Company entered into a Sponsored Research Agreement with Old Dominion University’s Frank Reidy Research Center for Bioelectrics, which includes certain intellectual property rights arising from the research. The Company is amortizing the intangible assets straight-line over an estimated useful life of 12 years.

Intangible assets, net consisted of the following (in thousands):

	September 30,			December 31,
	2025			2024
Acquired patents and licenses	$	8,005		$	7,985
Less: Accumulated amortization		(7,264	)		(6,765	)
Total intangible assets, net	$	741		$	1,220

A schedule of the amortization of intangible assets for the remainder of 2025 and the succeeding final year is as follows (in thousands):

Years ending December 31:
2025 (remaining 3 months)	$	166
2026		575
Total	$	741

Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	*September 30,*		*December 31,*
	*2025*		*2024*
Compensation expense	$	3,588	$	4,097
Clinical trial fees and costs		953		284
Professional fees		311		564
Legal settlement		—		1,196
Severance		—		698
Other		351		188
Total accrued expenses	$	5,203	$	7,027

Note 8 - Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Product revenue	$	86		$	—		$	86		$	—

Adjusted cost of product revenue¹		172			—			172			—
Cross platform research and engineering²		3,546			3,084			11,133			9,586
R&D manufacturing and engineering³		2,328			1,376			6,658			3,498
Clinical and regulatory⁴		2,363			1,245			5,902			2,913
General and administrative⁵		3,993			3,861			11,611			10,378
Sales and marketing⁶		2,177			813			5,997			1,937
Other segment items⁷		5,874			3,276			17,299			7,684
Total other income, net		(982	)		(975	)		(3,338	)		(1,796	)
Net loss	$	(19,385	)	$	(12,680	)	$	(55,348	)	$	(34,200	)

Note 7 - Commitments and Contingencies - Information Related to Right-of-use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Jun. 30, 2025	Dec. 31, 2024
Right-of-use assets	$ 6,316		$ 6,316	$ 7,163
Current operating lease liabilities	1,519			1,355
Non-current operating lease liabilities	6,371			7,543
Total lease liabilities	7,890			$ 8,898
Cash paid for operating lease liabilities	1,617	$ 1,425
2025 (remaining 3 months)	533
2026	2,225
2027	2,302
2028	2,381
2029	2,080
Thereafter	73
Total lease payments	9,594
Less imputed interest	$ (1,704)
Weighted-average remaining lease term (Year)	4 years 1 month 17 days
Weighted-average discount rate	9.80%

Note 6 - Stockholders' Equity and Stock-based Compensation

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

6. Stockholders’ Equity and Stock-Based Compensation

2024 Rights Offering and Subscription Rights

On March 28, 2024, the Company announced that its Board unanimously approved plans to initiate a rights offering, whereby the Company would distribute non-transferable subscription rights at no charge to all holders of the Company's common stock, par value $0.001 per share (the "Common Stock"), as of the close of business on a record date to be determined. On May 20, 2024, the Company announced that the Board had set May 31, 2024 as the record date (the "Record Date"). All holders of Common Stock as of the Record Date received non-transferable subscription rights to purchase up to an aggregate of six million units (the "2024 Units") with an aggregate offering value of up to $60 million (the "2024 Rights Offering") at a price per 2024 Unit equal to the lesser of: (i) $10 (the "Initial Price") and (ii) the volume weighted average price of the Common Stock for the ten trading day period through and including the expiration date, June 26, 2024 (the "Expiration Date"), of the Rights Offering (the "Alternate Price"). Each subscription right entitled the holder to purchase 0.10864186 2024 Units for each share of Common Stock owned as of the Record Date. Each 2024 Unit consisted of one share of Common Stock and two warrants, each being a warrant to purchase one-half of one share of Common Stock. The subscription rights were to expire and have no value if they were not exercised prior to the Expiration Date. The Company determined that the equity-classified subscription rights represent a pro-rata distribution issued to existing stockholders as of the Record Date, which is based on a purchase price of $10 per 2024 Unit as compared to (1) the price of $11.55 per one share of Common Stock on the Record Date, plus (2) the value of the warrants on the Record Date. The Company determined the fair value of the equity-classified subscription rights as of the Record Date, which involved the use of a Monte Carlo simulation model to value the underlying warrants. The Monte Carlo simulation model was based on certain significant unobservable inputs, such as a risk-free interest rate, stock price volatility, dividend yield, and expected term of the rights offering. The fair value of the equity-classified subscription rights was $47.7 million and was recorded in equity on the balance sheet as part of additional paid-in capital. The deemed pro-rata distribution to shareholders of $47.7 million was reflected as an offsetting reduction in additional paid-in capital. The Company is in an accumulated deficit position and has elected a policy of recognizing the deemed pro-rata distribution to shareholders as a reduction to additional paid-in capital rather than a further increase to its accumulated deficit.

On July 3, 2024, the Company announced the closing of its 2024 Rights Offering. The 2024 Rights Offering resulted in the sale of six million 2024 Units, at a price of $10.00 per 2024 Unit. Each 2024 Unit consisted of one share of the Company’s common stock, par value $0.001 per share, and two warrants, each being a warrant to purchase one-half of one share of common stock. The common stock and warrants comprising the 2024 Units separated upon the closing of the 2024 Rights Offering and were issued individually. A total of 5,999,998 shares of common stock and warrants to acquire up to approximately an additional six million shares of common stock were issued in the offering. The Company received aggregate gross proceeds from the 2024 Rights Offering of $60 million. See 2024 Rights Offering Warrants below for additional details of the warrants. Robert W. Duggan, the Company’s majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the 2024 Rights Offering.

Common Stock Warrants

2024 Rights Offering Warrants

In connection with the 2024 Rights Offering, the Company issued 2024 Rights Offering Warrants to purchase a total of 5,999,999 shares of its common stock at an exercise price of $11.00 per whole share, which equaled 110% of the subscription price for the Units. The aggregate number of shares of our common stock issuable upon the exercise of each set of warrants included in a given subscription for Units was rounded up to the nearest whole share. Warrants are exercisable immediately and will expire on the fifth anniversary of the closing of the 2024 Rights Offering. Half of the warrants issued in the rights offering were redeemable for $0.01 per underlying share of common stock, on not less than thirty days’ written notice, if the volume-weighted average price ("VWAP") of the Company’s common stock equaled or exceeded 150% of the exercise price for the warrants, or $16.50, for twenty consecutive trading days. In December 2024, the Company delivered an irrevocable notice of redemption to redeem this first tranche of common stock warrants because the VWAP of the Company's common stock over the twenty consecutive trading days before the notice was $18.85. Accordingly, pursuant to the 150% redemption feature, the Company redeemed 18,221 warrants on the redemption date, February 5, 2025, and none of these warrants are still outstanding. The other half of the warrants issued in the rights offering remain redeemable for $0.01 per underlying share of common stock, on not less than thirty days’ written notice, but only if the VWAP of the Company’s common stock equals or exceeds 200% of the exercise price for the warrants, or $22.00, for twenty consecutive trading days. As of September 30, 2025, there were no outstanding 2024 Rights Offering Warrants subject to the 150% redemption feature and there were 411,907 outstanding 2024 Rights Offering Warrants subject to the 200% redemption feature, entitling holders to purchase up to approximately 205,953 shares of common stock. During the nine-months ended September 30, 2025, we have received a total of $14.1 million in gross proceeds from exercises of the 2024 Rights Offering Warrants. Cumulatively, as of September 30, 2025, we have received a total of $63.5 million in gross proceeds from exercises of the 2024 Rights Offering Warrants.

Equity Plans

2017 Equity Incentive Plan and 2017 Inducement Equity Incentive Plan

The Board previously adopted, and the Company’s stockholders approved, the Company’s 2017 Equity Incentive Plan (the “2017 Plan”).

The 2017 Plan has a 10-year term and provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units ("RSUs"), performance units, and performance shares to employees, directors and consultants of the Company and any parent or subsidiary of the Company, as the Compensation Committee of the Board may determine. Subject to an annual evergreen increase and adjustment in the case of certain capitalization events, the Company initially reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to awards under the 2017 Plan. In addition, shares remaining available under the Company’s 2015 Equity Incentive Plan, as amended (the “2015 Plan”), and shares reserved but not issued pursuant to outstanding equity awards that expire or terminate without being exercised or that are forfeited or repurchased by the Company will be added to the shares of common stock available for issuance under the 2017 Plan. The 2017 Plan is administered by the Board’s Compensation Committee. Effective at both January 1, 2025 and 2024, the number of shares of common stock available under the 2017 Plan increased by 1,200,000, respectively, pursuant to the evergreen provision of the 2017 Plan. Under the evergreen provision of the 2017 Plan, the share increase is determined based on the least of (i) 1,200,000 shares, (ii) 4% of the Company’s common stock outstanding at December 31 of the immediately preceding year, or (iii) such number of shares as determined by the Board. Additionally, the number of shares of common stock available under the 2017 Plan increased by 1,375,000 shares as a result of a stockholder vote held at a special meeting of stockholders in December 2023. On September 30, 2025, the Company's stockholders approved an amendment to the 2017 Plan, which provided for an increase in the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares. As of September 30, 2025, a total of 1,072,564 of common stock remained available for issuance under the 2017 Plan.

During November 2017, the Board adopted the 2017 Inducement Equity Incentive Plan (the “Inducement Plan”) and reserved 1,000,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan was adopted without stockholder approval.

The Inducement Plan has a 10-year term and provides for the grant of equity-based awards, including non-statutory stock options, RSUs, restricted stock, stock appreciation rights, performance shares, and performance units, and its terms are substantially similar to the 2017 Plan, including with respect to treatment of equity awards in the event of a “merger” or “change in control” as defined under the Inducement Plan. Options issued under the Inducement Plan may have a term up to ten years and have variable vesting provisions. New hire stock option grants to non-executive employees generally vest 25% per year starting upon the first anniversary of the grant. New hire stock option grants to executive employees may contain time-based, performance-based, and/or market-based vesting. Equity-based awards issued under the Inducement Plan are only issuable to individuals not previously engaged as employees or individuals returning to employment with the Company following a bona-fide period of non-employment. In May 2021, the Board approved an amendment to the Inducement Plan to reserve an additional 1,000,000 shares of the Company’s common stock for issuance pursuant to the Inducement Plan. And, in March 2024, the Board approved a second amendment to the Inducement Plan to reserve an additional 2,000,000 shares of the Company’s common stock for issuance pursuant to the Inducement Plan. As of September 30, 2025, 2,328,709 shares of common stock remained available for issuance under the Inducement Plan.

A summary of stock option activity under the 2015 Plan, 2017 Plan, and Inducement Plan for the nine-months ended September 30, 2025 is presented below:

	*Stock Options Outstanding*
	*Number of shares*			*Weighted average exercise price*		*Weighted average remaining life (in years)*
Balances — December 31, 2024		10,979,332		$	9.59		7.11
Options granted		2,884,343			18.67
Options exercised		(493,431	)		4.26
Options canceled		(66,500	)		13.13
Options expired		—			—
Balances — September 30, 2025		13,303,744		$	11.74		7.24
Exercisable — September 30, 2025		4,806,075		$	13.44		5.20

Time-based Options

The Company awards time-based options which vest and become exercisable, subject to the individual’s continued employment or service through the applicable vesting date. Time-based options can have various vesting schedules, most commonly new hire grants which generally vest 25% per year starting upon the first anniversary of the grant. As of September 30, 2025, and December 31, 2024, time-based options outstanding were 8,939,677 and 8,075,265 shares, respectively. During the nine-months ended September 30, 2025, the Company granted 1,424,343 time-based options with an aggregate grant date fair value of $20.9 million.

Performance-based Options

Certain stock options awarded by the Company contain performance conditions related to certain financial measures and achievements of strategic and operational milestones. Once a specific performance condition is fulfilled, the associated options will fully vest and become exercisable. As of September 30, 2025 and December 31, 2024, performance-based options outstanding were 442,678 shares. There were no performance-based options granted during the nine-months ended September 30, 2025.

The fair value of time-based and performance-based stock options granted were determined using the Black-Scholes option pricing model. The following summarizes the range of assumptions used in calculating the fair value of the awards:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Expected term in years		5.2 - 6.3		5.0 - 6.3		5.0 - 6.9		5.0 - 6.3
Expected volatility		93% - 95%		93% - 97%		93% - 100%		91% - 97%
Risk-free interest rate		4.0% - 4.1%		4.5%		4.0% - 4.6%		4.0% - 4.5%
Dividend yield		—		—		—		—

Market-based Options

Certain stock options awarded by the Company contain market conditions related to achievement of certain market capitalization targets. The options will vest and become exercisable once the specific market capitalization targets are fulfilled. As of September 30, 2025, and December 31, 2024, market-based options outstanding were 2,721,389 and 2,461,389 shares, respectively. During the nine-months ended September 30, 2025, the Company granted 260,000 market-based options with an aggregate grant date fair value of $4.0 million.

The fair value of market-based stock options granted were determined using the Monte Carlo simulation model. The following summarizes the range of assumptions used in calculating the fair value of the awards:

	Three Months Ended September 30,				Nine Months Ended September 30,
	*2025*		*2024*		*2025*		*2024*
Expected term in years		2.2 - 4.5		2.2 - 4.2		2.2 - 7.0		2.2 - 5.8
Expected volatility		90%		90%		90%		90%
Risk-free interest rate		3.9%		3.9%		3.9% - 4.6%		3.9% - 4.4%
Dividend yield		—		—		—		—

Market and Performance-based Options

Certain stock options awarded by the Company contain market conditions related to the achievement of certain market capitalization targets as well as the achievement of certain revenue and margin metrics. The options will vest and become exercisable once both the specific market capitalization targets as well as the specific revenue and margin targets are fulfilled. As of September 30, 2025, market and performance-based options outstanding were 1,200,000 shares. There were no market and performance-based options outstanding as of December 31, 2024. During the nine-months ended September 30, 2025, the Company granted 1,200,000 market and performance-based options with an aggregate grant date fair value of $18.9 million. There were no market and performance-based options granted during the three-months ended September 30, 2025.

As of September 30, 2025, the Company determined it is not probable that any of the performance conditions in these grants will be achieved and therefore did not recognize any associated stock-based compensation expense during the nine-months ended September 30, 2025. The Company will reassess the probability of these performance conditions at each reporting period. The fair value of market-based stock options granted was determined using the Monte Carlo simulation model. The following summarizes the range of assumptions used in calculating the fair value of the awards:

	Three Months Ended September 30,				Nine Months Ended September 30,
	*2025*		*2024*		*2025*		*2024*
Expected term in years		—		—		6.1 - 8.9		—
Expected volatility		—		—		90%		—
Risk-free interest rate		—		—		4.4% - 4.6%		—
Dividend yield		—		—		—		—

2017 Employee Stock Purchase Plan

The Board previously adopted, and the Company's stockholders approved, the Company’s 2017 Employee Stock Purchase Plan (the “2017 ESPP”).

The 2017 ESPP is a broad-based plan that provides employees of the Company and its designated affiliates with the opportunity to become stockholders through periodic payroll deductions that are applied towards the purchase of Company common shares at a discount from the then-current market price. Subject to adjustment in the case of certain capitalization events, a total of 250,000 common shares of the Company were available for purchase at adoption of the 2017 ESPP. Pursuant to the 2017 ESPP, the annual share increase pursuant to the evergreen provision is determined based on the least of (i) 450,000 shares, (ii) 1.5% of the Company’s common stock outstanding at December 31 of the immediately preceding year, or (iii) such number of shares as determined by the Board. In January 2025 and 2024, the Company reserved an additional 450,000 shares, respectively, under the 2017 ESPP pursuant to the evergreen provision. During the nine-months ended September 30, 2025, the Company issued 44,596 shares of common stock under the 2017 ESPP. As of September 30, 2025, 851,183 shares of common stock remained available for issuance under the 2017 ESPP.

The fair value of ESPP grants was determined using the Black-Scholes option pricing model. The following summarizes the range of assumptions used in calculating the fair value of the awards:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Expected term in years		0.5 - 1.0		0.5 - 1.0		0.5 - 1.0		0.5 - 1.0
Expected volatility		98%		98%		98%		98%
Risk-free interest rate		3.8% - 4.0%		4.4% - 5.3%		3.8% - 4.3%		4.9% - 5.3%
Dividend yield		—		—		—		—

Stock-based Compensation

Total stock-based compensation expense consisted of the following (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	*2025*		*2024*		*2025*		*2024*
Cost of product revenue	$	52	$	—	$	52	$	—
Research and development		2,232		1,108		7,329		3,058
Selling, general and administrative		3,333		1,874		9,106		3,735
Total stock-based compensation expense	$	5,617	$	2,982	$	16,487	$	6,793

As of September 30, 2025, none of the performance conditions of the performance-based and market and performance-based options are probable to be achieved, and as such, no expense has been recognized during the three and nine-months ended September 30, 2025.

Total stock-based compensation expense by award type was as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	*2025*		*2024*		*2025*		*2024*
Time-based options	$	3,937	$	2,131	$	11,623	$	4,609
Performance-based options		—		5		—		27
Market-based options		1,577		788		4,581		1,978
ESPP		103		58		283		179
Total stock-based compensation expense	$	5,617	$	2,982	$	16,487	$	6,793

Note 7 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating Lease, Expense	$ 0.6	$ 0.6	$ 1.9	$ 1.8

Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Total stock-based compensation expense	$ 5,617	$ 2,982	$ 16,487	$ 6,793
Share-Based Payment Arrangement, Expense	5,617	2,982	16,487	6,793
Time-based Options [Member]
Total stock-based compensation expense	3,937	2,131	11,623	4,609
Share-Based Payment Arrangement, Expense	3,937	2,131	11,623	4,609
Performance-based Options [Member]
Total stock-based compensation expense	0	5	0	27
Share-Based Payment Arrangement, Expense	0	5	0	27
Market-based Options [Member]
Total stock-based compensation expense	1,577	788	4,581	1,978
Share-Based Payment Arrangement, Expense	1,577	788	4,581	1,978
Employee Stock Purchase Plan Award [Member]
Total stock-based compensation expense	103	58	283	179
Share-Based Payment Arrangement, Expense	103	58	283	179
Cost of Sales [Member]
Total stock-based compensation expense	52	0	52	0
Share-Based Payment Arrangement, Expense	52	0	52	0
Research and Development Expense [Member]
Total stock-based compensation expense	2,232	1,108	7,329	3,058
Share-Based Payment Arrangement, Expense	2,232	1,108	7,329	3,058
Selling, General and Administrative Expenses [Member]
Total stock-based compensation expense	3,333	1,874	9,106	3,735
Share-Based Payment Arrangement, Expense	$ 3,333	$ 1,874	$ 9,106	$ 3,735

Note 3 - Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

		September 30, 2025
Assets	Classification	Level 1		Level 2		Level 3		Total
Money market funds	Cash and cash equivalents	$	90,156	$	—	$	—	$	90,156
Total assets measured at fair value		$	90,156	$	—	$	—	$	90,156

		*December 31, 2024*
Assets	*Classification*	*Level 1*		*Level 2*		*Level 3*		*Total*
Money market funds	Cash and cash equivalents	$	113,776	$	—	$	—	$	113,776
Total assets measured at fair value		$	113,776	$	—	$	—	$	113,776

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net loss	$ (55,348)	$ (34,200)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	313	391
Amortization of intangible assets	499	500
Stock-based compensation	16,487	6,793
Non-cash lease expense	847	668
Changes in operating assets and liabilities:
Accounts receivable	(15)	0
Inventory	(57)	0
Prepaid expenses and other current assets	(538)	(394)
Other receivables	(14)	7
Other long-term assets	(28)	0
Accounts payable	1,318	(194)
Accrued expenses	(1,823)	7
Lease liabilities	(1,008)	(777)
Net cash used in operating activities	(39,367)	(27,199)
Cash flows from investing activities:
Purchases of property and equipment	(210)	(72)
Purchases of intangible assets	(20)	0
Net cash used in investing activities	(230)	(72)
Cash flows from financing activities:
Proceeds from issuance of common stock under employee stock purchase plan	593	478
Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs	0	59,649
Proceeds from exercises of warrants, net of issuance costs	14,080	1,536
Proceeds from exercises of stock options	2,100	498
Issuance costs in relation to at-the-market equity offering	0	(222)
Net cash provided by financing activities	16,773	61,939
Net (decrease) increase in cash and cash equivalents	(22,824)	34,668
Cash and cash equivalents at beginning of period	118,038	44,365
Cash and cash equivalents at end of period	95,214	79,033
Supplemental disclosure of noncash investing and financing activities:
Equipment purchases included in accounts payable and accrued expenses	24	13
Issuance costs in accounts payable and accrued expenses	1	72
Other receivable from exercises of warrants	0	30
Rights offering deemed pro-rata distribution to shareholders	$ 0	$ 47,700

Note 4 - Balance Sheet Components - Schedule of Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
2025 (remaining 3 months)	$ 166
2026	575
Total	$ 741	$ 1,220

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Rights Offering Warrants [Member]
Issuance cost	$ 2		$ 16
Rights Offering [Member]
Issuance cost		$ 364		$ 364
ATM Offering [Member]
Issuance cost		$ 24		$ 24

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2025

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company’s December 31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The condensed consolidated financial statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2024 was derived from the audited consolidated financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. The results of operations for the three and nine-months ended September 30, 2025, are not necessarily indicative of the results to be expected for the entire year or any future periods.

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

The accompanying condensed consolidated financial statements include the financial statements of Pulse Biosciences, Inc. and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Estimates include, but are not limited to, the valuation and recognition of stock-based compensation, the valuation of equity-classified subscription rights, inventory valuation, income taxes, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.

Share-Based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

The Company's stock-based compensation programs include stock options and an employee stock purchase program.

The Company periodically issues stock options to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors and employees, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values, which are estimated using the Black-Scholes option-pricing model. Stock-based compensation expense is charged to operations on a straight-line basis over the vesting period. The Company has granted stock options with both time-based as well as performance-based vesting conditions. For stock awards with performance-based vesting conditions, the Company does not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved. The analysis to determine such probability involves estimates and judgements from management and the estimate of expense may be revised periodically. In October 2024, the Board approved changes to the vesting conditions of certain outstanding common stock option awards so that the performance-based vesting criteria of those particular awards were modified to either time-based or market-based vesting criteria.

During 2024, the Company issued certain stock options with market-based vesting conditions and modified certain performance-based stock option awards to market-based options. These vesting conditions relate to the achievement of certain market capitalization targets of the Company. Using a Monte Carlo simulation model, the Company estimated the fair value of the market-based options on the grant date or modification date, with the associated stock-based compensation expense recognized over the requisite service period. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, the Company will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares.

In the first quarter of 2025, the Company issued certain executives stock options with both market-based and performance-based vesting conditions. These vesting conditions relate to both the achievement of certain market capitalization targets of the Company, as well as the achievement of certain revenue and margin metrics. Using a Monte Carlo simulation model, the Company estimated the fair value of the market-based options on the grant date, along with a derived service period. Compensation expense for the awards is recognized over the requisite service period, which is the longer of the derived service period or the implicit service period (the period when the performance condition is expected to be met). Compensation expense is recognized only once it becomes probable that the associated performance condition will be achieved and the employee is expected to render the requisite service. Once these criteria are met, the Company will recognize expense using the accelerated attribution method over the requisite service period. If, at any point, the performance condition is no longer probable of being achieved or the employee is no longer expected to complete the requisite service period, any previously recognized expense will be reversed. Additionally, if both the market and performance conditions are satisfied before the end of the requisite service period, any remaining unrecognized expense will be recognized immediately, provided that the employee is still providing service.

The Monte Carlo simulation models require the Company to make assumptions and judgements about the variables used in the calculations including the expected volatility, the risk-free interest rate, cost of equity, and the expected term. The assumptions used in the option-pricing model represent management’s best estimates. If factors change and different assumptions are used, the Company's stock-based compensation expense could be materially different in the future.

See Note 6 for a detailed discussion of the Company’s stock plans and stock-based compensation expense.

Inventory, Policy [Policy Text Block]

Valuation of Inventory

During the nine-months ended September 30, 2025, the Company determined that costs had future economic benefit subsequent to receiving FDA approval, and as such, it began to capitalize inventory in preparation of its limited market release of percutaneous electrodes for its Vybrance Percutaneous Electrode System. Prior to capitalizing inventory, all direct and indirect manufacturing costs were charged to research and development expenses in the period incurred or written off as excess and obsolete inventory in 2022, including previously manufactured consoles.

Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the purchase costs on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of the Company’s business, less reasonably predictable costs of completion, disposal, and transportation. The cost basis of the Company’s inventory will be reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. During the nine-months ended September 30, 2025, there was no reduction to the balance of inventory for excessive and obsolete inventory.

Revenue from Contract with Customer [Policy Text Block]

Revenue from Contracts with Customers

The Company accounts for a contract with a customer when the rights and obligations of the parties are identifiable, the contract has commercial substance, and the collectability of the consideration to be received from the customer is considered probable. Contracts with customers are for the sale of the nPulse Vybrance system, which includes system components, software, and system accessories. Instruments and other accessories may also be included with the system or may be sold on a standalone basis. These products are considered performance obligations to the extent they are separately identifiable from other products in the contract and when the customer can either benefit from the product on its own or with other goods or services that are readily available to the customer.

The Company recognizes revenue at a point in time when it satisfies performance obligations by transferring control of promised goods to its customers. Transfer of control occurs based on shipping terms as contractually negotiated. The amount of revenue recognized is equal to the consideration to which the Company expects to be entitled in exchange for the promised goods. Though some products may be sold on a stand-alone basis, initial customer contracts will likely involve the bundling of products which will be delivered concurrently to the customer for a single price. The initial limited market release period will also include evaluation agreements with customers that allow either the Company or the customer to terminate the contract at any point without penalty. The termination right limits the effective contract term to the period for which the contract was not terminated. The Company generally extends payment terms to customers after the Company performs a necessary credit evaluation to ensure future collectability of the outstanding balance. Payment generally occurs within a relatively short period of time after delivery of products.

The transaction price is the consideration to which the Company expects to be entitled in exchange for providing the promised goods to customers. Though most customer orders are for a fixed amount of consideration, the Company evaluates the possible impact of variable consideration in determining the transaction price, in particular the possibility of future returns. Sales agreements allow for a right of return only if the product does not conform to the agreed upon quality standards or if the product was shipped due to Company error. The Company anticipates such returns will be minimal and has made no adjustments to the transaction price for any estimated returns. The transaction price is determined at contract execution and updated each quarter for any changes in circumstances (e.g., changes in estimated return amount).

The Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes which are imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.

When there are multiple performance obligations present, the total transaction price shall be allocated to each of the performance obligations based upon the relative standalone selling price (“SSP”) of those performance obligations. The Company establishes SSPs based on multiple factors including prices charged by the Company for similar offerings, product-specific business objectives, and the estimated cost to provide the performance obligation.

Shipping and handling activities are not considered to be a separate performance obligation. The Company has made an accounting policy election to account for shipping and handling activities as fulfillment activities when these activities occur after the customer obtains control of the product.

The Company has determined that certain promises in the multiple-element arrangements, such as installation, training, and certain ancillary products, are immaterial in the context of the contract and do not represent separate performance obligations to which transaction price is allocated.

The Company utilizes the practical expedient under ASC 606 and does not disclose unsatisfied performance obligations for contracts as the contracts generally have an original duration of less than one year. Additionally, the Company does not currently have significant contract assets or deferred revenue.

The Company does not incur contract origination costs.

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share.

Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive.

The following outstanding stock options and warrants were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:

	Nine Months Ended September 30,
	*2025*		*2024*
Common stock warrants		205,953		5,857,680
Common stock options		13,303,744		12,327,332
Total		13,509,697		18,185,012

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassification

Certain reclassifications have been made to the prior period presentation of the cash flows from operating activities within the condensed consolidated statements of cash flows to conform to current period presentation. Specifically, the presentation of operating lease expenses has been reclassified from “Right-of-use assets” within “Changes in operating assets and liabilities” to “Non-cash lease expense” within “Adjustments to reconcile net loss to net cash used in operating activities”. Additionally, certain reclassifications have been made to the prior period presentation of other income within the condensed consolidated statements of operations and comprehensive loss to conform to current period presentation. Specifically, the presentation of "Other expense" has been reclassified out of "Interest income, net." As a result of these changes, the presentation of these expenses in the comparative periods has been changed to conform to the current period. These reclassifications did not have an impact on the Company’s results of operations and total cash flows from operating activities for the three and nine-months ended September 30, 2025 and 2024, respectively, or the Company's financial position as of September 30, 2025 and December 31, 2024.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. This ASU should be applied on a prospective basis although retrospective application is permitted. While the Company is still evaluating the full impact of the adoption of this ASU, it does not expect it to have a material impact on its consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which aims to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. The guidance is effective for the Company's annual periods beginning in 2027 and interim periods beginning in the first quarter of fiscal year 2028. The Company is currently evaluating the impact of the new guidance.

In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient to measure credit losses on current accounts receivable and current contract assets under Accounting Standards Codification 606, Revenue from Contracts with Customers. The practical expedient assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. The guidance is effective for the Company's interim and annual periods beginning in 2026. The Company is currently evaluating the impact of the new guidance.

Income Tax, Policy [Policy Text Block]

Recent Tax Legislation

During the three months ended September 30, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted. The Company does not anticipate a material impact to income tax expense for the year ended December 31, 2025 as a result of OBBBA.

Note 2 - Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Significant Accounting Policies [Text Block]

2. Summary of Significant Accounting Policies

Basis of Presentation

Principles of Consolidation

Use of Estimates

Significant Accounting Policies

The Company’s significant accounting policies are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. The Company continually evaluates the accounting policies and estimates used in preparing the consolidated financial statements.

Stock-Based Compensation

The Company's stock-based compensation programs include stock options and an employee stock purchase program.

See Note 6 for a detailed discussion of the Company’s stock plans and stock-based compensation expense.

Valuation of Inventory

Revenue from Contracts with Customers

The Company does not incur contract origination costs.

Net Loss per Share

Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive.

	Nine Months Ended September 30,
	*2025*		*2024*
Common stock warrants		205,953		5,857,680
Common stock options		13,303,744		12,327,332
Total		13,509,697		18,185,012

Reclassification

Recent Accounting Pronouncements

Recent Tax Legislation

Note 6 - Stockholders' Equity and Stock-based Compensation (Details Textual) $ / shares in Units, $ in Thousands						1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended	18 Months Ended
	Sep. 30, 2025 $ / shares shares	Feb. 05, 2025 shares	Jan. 01, 2025 shares	Jul. 03, 2024 USD ($) $ / shares shares	Mar. 28, 2024 USD ($) $ / shares shares	Jan. 31, 2025 shares	Dec. 31, 2024 $ / shares shares	Mar. 31, 2024 shares	Nov. 30, 2017 shares	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Dec. 31, 2017 shares	Sep. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2025 $ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.001						$ 0.001			$ 0.001		$ 0.001			$ 0.001
Equity Classified Subscription, Value \| $													$ 47,700
Right Offering Deemed Dividend \| $												$ 0	47,700
Proceeds from Warrant Exercises \| $												14,080	1,536
Share-Based Payment Arrangement, Expense \| $										$ 5,617	$ 2,982	$ 16,487	6,793
Time-based Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	8,939,677						8,075,265			8,939,677		8,939,677			8,939,677
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												1,424,343
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value \| $												$ 20,900
Share-Based Payment Arrangement, Expense \| $										$ 3,937	2,131	$ 11,623	4,609
Performance-based Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	442,678						442,678			442,678		442,678			442,678
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												0
Share-Based Payment Arrangement, Expense \| $										$ 0	5	$ 0	27
Market-based Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	2,721,389						2,461,389			2,721,389		2,721,389			2,721,389
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												260,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value \| $												$ 4,000
Share-Based Payment Arrangement, Expense \| $										$ 1,577	$ 788	$ 4,581	$ 1,978
Performance-based and Market-based Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	1,200,000						0			1,200,000		1,200,000			1,200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												1,200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value \| $												$ 18,900
Share-Based Payment Arrangement, Expense \| $										$ 0		$ 0
The 2017 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)														10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)														1,500,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	2,000,000		1,200,000				1,375,000
Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Number of Shares (in shares)														1,200,000
Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Percent														4.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	1,072,564									1,072,564		1,072,564			1,072,564
The 2017 Inducement Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)									10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)									1,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)								2,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	2,328,709									2,328,709		2,328,709			2,328,709
The 2017 Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)														250,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)						450,000
Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Number of Shares (in shares)														450,000
Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Percent														1.50%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	851,183									851,183		851,183			851,183
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)												44,596
Share-Based Payment Arrangement, Tranche One [Member] \| Time-based Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage												25.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)												1 year
Share-Based Payment Arrangement, Tranche One [Member] \| The 2017 Inducement Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage									25.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)									1 year
Maximum [Member] \| The 2017 Inducement Equity Incentive Plan [Member] \| Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)									10 years
Warrants Issued in 2024 Rights Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				0.5	0.5
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	205,953			5,999,999						205,953		205,953			205,953
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares				$ 11
Class of Warrans or Right, Exercise Price, Percentage of Subscription Price for Units				110.00%
Warrants and Rights Outstanding, Term (Year)				5 years
Proceeds from Warrant Exercises \| $												$ 14,100			$ 63,500
Warrants Issued in 2024 Rights Offering [Member] \| Vesting of First Half [Member]
Class of Warrants or Rights, Redemption Price Per Share (in dollars per share) \| $ / shares				$ 0.01
Class of Warrant or Right, Percentage Required for Redemption	150.00%	150.00%		150.00%						150.00%		150.00%			150.00%
Class of Warrant or Right, Vesting, Stock Price Trigger (in dollars per share) \| $ / shares				$ 16.5												$ 18.85
Class of Warrant or Right, Expired/Redeemed During Period (in shares)		18,221
Class of Warrant or Right, Outstanding (in shares)	0	0								0		0			0
Warrants Issued in 2024 Rights Offering [Member] \| Vesting of Second Half [Member]
Class of Warrants or Rights, Redemption Price Per Share (in dollars per share) \| $ / shares				$ 0.01
Class of Warrant or Right, Percentage Required for Redemption	200.00%			200.00%						200.00%		200.00%			200.00%
Class of Warrant or Right, Vesting, Stock Price Trigger (in dollars per share) \| $ / shares				$ 22
Class of Warrant or Right, Outstanding (in shares)	411,907									411,907		411,907			411,907
Warrants Issued in 2024 Rights Offering [Member] \| Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				6,000,000
The 2024 Right Offering [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares				$ 0.001	$ 0.001
Equity Offering, Units, Maximum Amount Authorized (in shares)				6,000,000	6,000,000
Equity Offering Units, Offering Value \| $					$ 60,000
Shares Issued, Price Per Share (in dollars per share) \| $ / shares				$ 10	$ 10
Subscription Right, Number of Units					0.10864186
Number of Shares Per Unit Issued (in shares)				1	1
Number of Warrants in Each Unit (in shares)				2	2
Share Price (in dollars per share) \| $ / shares					$ 11.55
Equity Classified Subscription, Value \| $					$ 47,700
Right Offering Deemed Dividend \| $					$ 47,700
Stock Issued During Period, Shares, New Issues (in shares)				5,999,998
Proceeds from Issuance or Sale of Equity \| $				$ 60,000
The 2024 Right Offering [Member] \| Majority Stockholder and Co-chairman [Member]
Percent of Offering Purchased				88.00%

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenue:
Product revenue	$ 86	$ 0	$ 86	$ 0
Cost and expenses:
Cost of product revenue	279	0	279	0
Research and development	11,393	7,703	33,794	21,674
Selling, general and administrative	8,781	5,952	24,699	14,322
Total cost and expenses	20,453	13,655	58,772	35,996
Loss from operations	(20,367)	(13,655)	(58,686)	(35,996)
Other income (expense):
Interest income	1,001	976	3,385	1,804
Other expense	(19)	(1)	(47)	(8)
Total other income	982	975	3,338	1,796
Net loss	(19,385)	(12,680)	(55,348)	(34,200)
Comprehensive loss	$ (19,385)	$ (12,680)	$ (55,348)	$ (34,200)
Net loss per share, basic and diluted (in dollars per share)	$ (0.29)	$ (0.21)	$ (0.82)	$ (0.6)
Weighted average common shares outstanding, basic and diluted (in shares)	67,385	61,066	67,263	57,169

Note 7 - Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Schedule of Information Related to Right-of-use Assets and Lease Liabilities [Table Text Block]

	September 30,		December 31,
Assets:	2025		2024
Right-of-use assets	$	6,316	$	7,163

	*September 30,*		*December 31,*
Liabilities:	*2025*		*2024*
Current operating lease liabilities	$	1,519	$	1,355
Non-current operating lease liabilities		6,371		7,543
Total lease liabilities	$	7,890	$	8,898

Nine Months Ended

September 30,

2025

2024

Cash paid for operating lease liabilities

1,617

1,425

Year ending December 31:
2025 (remaining 3 months)	$	533
2026		2,225
2027		2,302
2028		2,381
2029		2,080
Thereafter		73
Total lease payments		9,594
Less imputed interest		(1,704	)
Total lease liabilities	$	7,890

Weighted-average remaining lease term			4.13
Weighted-average discount rate			9.8	%

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2025	Oct. 31, 2025
Document Information [Line Items]
Entity Central Index Key	0001625101
Entity Registrant Name	Pulse Biosciences, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2025
Document Transition Report	false
Entity File Number	001-34899
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-5696597
Entity Address, Address Line One	601 Brickell Key Drive, Suite 1080
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33131
City Area Code	510
Local Phone Number	906-4600
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	PLSE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		67,767,578

Note 5 - Goodwill

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Goodwill Disclosure [Text Block]

5. Goodwill

In 2014, the Company acquired three companies (the “Acquisitions”) for aggregate consideration of $5.5 million. In accordance with ASC Topic 805, Business Combinations, the Company recorded goodwill of $2.8 million in connection with the Acquisitions as the consideration paid exceeded the fair value of the net tangible assets and the intangible assets acquired.

In accordance with ASC Topic 350, Intangibles-Goodwill and Other, the Company reviews goodwill for impairment at least annually or whenever any events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. As of September 30, 2025, there were no indicators of impairment and it was determined that no impairment of goodwill existed.

- Definition

The entire disclosure for goodwill.

+ References + Details

Note 3 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Fair Value, Recurring [Member]
Liabilities, Fair Value Disclosure	$ 0	$ 0

Note 7 - Commitments and Contingencies

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

7. Commitments and Contingencies

Operating Leases

The Company leases office and laboratory facilities for its principal operations in Hayward, California, and office facilities for its corporate headquarters in Miami, Florida. These lease arrangements are both classified as operating leases.

Supplemental balance sheet information related to leases (in thousands):

	September 30,		December 31,
Assets:	2025		2024
Right-of-use assets	$	6,316	$	7,163

	*September 30,*		*December 31,*
Liabilities:	*2025*		*2024*
Current operating lease liabilities	$	1,519	$	1,355
Non-current operating lease liabilities		6,371		7,543
Total lease liabilities	$	7,890	$	8,898

Total cash paid for operating lease liabilities (in thousands):

Nine Months Ended

September 30,

2025

2024

Cash paid for operating lease liabilities

1,617

1,425

Maturities of operating lease liabilities were as follows (in thousands):

Year ending December 31:
2025 (remaining 3 months)	$	533
2026		2,225
2027		2,302
2028		2,381
2029		2,080
Thereafter		73
Total lease payments		9,594
Less imputed interest		(1,704	)
Total lease liabilities	$	7,890

Weighted-average remaining lease term and discount rate, as of September 30, 2025, were as follows:

Weighted-average remaining lease term			4.13
Weighted-average discount rate			9.8	%

Rent expense, including common area maintenance charges, was approximately $0.6 million for each of the three-months ended September 30, 2025 and 2024, and approximately $1.9 million and $1.8 million for the nine-months ended September 30, 2025 and 2024, respectively.

Legal Proceedings

From time to time, we may be involved in various legal proceedings arising in the ordinary course of business. We are not presently a party to any legal proceedings that, in the opinion of management, could have a material adverse effect on our results of operations or financial condition. Regardless of outcome, however, any litigation could have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm, and other factors.